Anupam Rasayan Bliss GVS Pharma Acquisition: Controlling Stake Completed

• Anupam Rasayan India Limited, through its subsidiary, acquired 47.95% of Bliss GVS Pharma Limited's equity shares.
• The acquisition was completed via a share purchase agreement and a subsequent mandatory open offer.
• Kanga & Co advised the sellers on transaction documentation, the open offer process, and regulatory compliance.
• Bliss GVS Pharma specializes in the development and manufacturing of suppositories, pessaries, and various branded pharmaceutical products.
• Anupam Rasayan India will gain controlling stake over Bliss GVS Pharma following the transaction.

For legal professionals advising on M&A transactions in India, this deal serves as a contemporary illustration of a controlling stake acquisition that necessitated a mandatory open offer, highlighting the detailed legal work involved in managing transaction documentation, regulatory submissions, and compliance for the selling parties under Indian corporate and securities laws.

Anupam Rasayan India Limited has successfully completed a significant acquisition, securing a controlling interest in Bliss GVS Pharma Limited. This strategic move involved Anupam Rasayan's wholly owned subsidiary, Mates Visa Consultancy Private Limited, purchasing a substantial block of 5,09,86,264 equity shares. These shares collectively represent 47.95% of Bliss GVS Pharma's total equity share capital, effectively transferring a majority stake and control to the acquiring entity.

The acquisition was executed through a two-pronged approach, commencing with an initial share purchase agreement and subsequently triggering a mandatory open offer, as required by Indian regulations for such substantial stake purchases. The share purchase agreement was finalized between Anupam Rasayan India and the selling parties, which included the promoters of Bliss GVS Pharma along with various other shareholders. This comprehensive transaction ensures Anupam Rasayan India's direct and complete control over Bliss GVS Pharma upon its completion, marking a significant expansion for the chemical manufacturer into the pharmaceutical domain.

The sellers in this substantial transaction, comprising the promoters and other shareholders of Bliss GVS Pharma, received expert legal counsel from Kanga & Co. The Mumbai-based law firm's mandate encompassed a broad range of advisory services, crucial for navigating the complexities of such a large-scale acquisition in the Indian market. Their assistance was vital throughout the entire process, from the initial stages of execution to the final completion of the deal.

Kanga & Co's advisory role specifically included comprehensive guidance on the intricate transaction documentation, ensuring all legal instruments were robust, enforceable, and fully compliant with relevant statutes. Furthermore, they provided extensive support regarding the mandatory open offer process, a critical regulatory requirement for controlling stake acquisitions in India. This involved meticulous attention to related regulatory disclosures and adherence to all applicable compliances, ensuring a smooth and legally sound transfer of ownership. The legal team was notably led by Senior Partner Chetan Thakkar, with Senior Associate Jalees Shaikh focusing on transaction documents. Principal Associate Tejal Patankar, alongside Associates Sachi Ray, Vansh Chadha, Suphla Singh, and Meghna Sharma, expertly handled the open offer and securities law aspects.

This acquisition is particularly noteworthy given Bliss GVS Pharma's specialized and established position within the pharmaceutical sector. The company is recognized for its expertise in the development and manufacturing of suppositories and pessaries, a niche but important area of pharmaceutical delivery. Beyond these specialized forms, Bliss GVS Pharma also produces a diverse range of branded products, including anti-malarials, contraceptives, anti-infectives, and gastrointestinal medications, indicating a broad and varied product portfolio.

The successful completion of this transaction means Anupam Rasayan India will now exert direct control over Bliss GVS Pharma's operations and strategic direction, integrating its new acquisition into its broader business strategy. For legal professionals advising on M&A transactions in India, this deal serves as a contemporary illustration of a controlling stake acquisition that necessitated a mandatory open offer, highlighting the detailed legal work involved in managing transaction documentation, regulatory submissions, and compliance for the selling parties under Indian corporate and securities laws.

Lawyers advising on M&A transactions in India can examine this deal as a recent example of a controlling stake acquisition involving a mandatory open offer, noting the legal complexities handled by Kanga & Co regarding transaction documentation, regulatory disclosures, and compliance for the sellers.

Source: Original reporting via Bar & Bench